Cells for Research and Therapy

Our Company

International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.

Company >>

Products in Development

ISCO scientists are using human parthenogenetic stem cells (hpSC) to treat severe diseases of the central nervous system, joints and liver, where cell therapy has shown clinical benefit but treatment options are limited by the availability of human cells.

Pipeline >>

News & Events

News & Events >>